Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Neeser

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Disease Management : DM|August 9, 2006
Using individualized predictive disease modeling to identify patients with the potential to benefit from a disease management program for diabetes mellitusChristian Weber, Kurt Neeser
Diabetes Technology & Therapeutics|August 25, 2009
Cost impact of self-measurement of blood glucose on complications of type 2 diabetes: the Spanish perspectiveKurt Neeser, Christian Weber
Journal of Diabetes Science and Technology|October 6, 2010
Glucose information for tight glycemic control: different methods with different challengesChristian Weber, Kurt Neeser
Current Medical Research and Opinion|December 2, 2009
Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspectiveChristian Weber, Serge Kocher, Kurt Neeser, et al.
Pharmacoeconomics|April 6, 2004
Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspectiveKurt Neeser, Georg Lübben, Uwe Siebert, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessmentChristian Weber, Kurt Neeser, Berthold Schneider, et al.
Current Medical Research and Opinion|March 31, 2009
Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overviewChristian Weber, Serge Kocher, Kurt Neeser, et al.
Journal of Comparative Effectiveness Research|April 3, 2019
Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapyKurt Neeser, William M O'Neil, Lee Stern, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2007
Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factorsKurt Neeser, Thomas Szucs, Jean-Luc Bulliard, et al.
Swiss Medical Weekly|November 9, 2007
Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11)Christian Weber, Berthold Schneider, Volker Lodwig, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Disease Management : DM|August 9, 2006
Using individualized predictive disease modeling to identify patients with the potential to benefit from a disease management program for diabetes mellitusChristian Weber, Kurt Neeser
Diabetes Technology & Therapeutics|August 25, 2009
Cost impact of self-measurement of blood glucose on complications of type 2 diabetes: the Spanish perspectiveKurt Neeser, Christian Weber
Journal of Diabetes Science and Technology|October 6, 2010
Glucose information for tight glycemic control: different methods with different challengesChristian Weber, Kurt Neeser
Current Medical Research and Opinion|December 2, 2009
Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspectiveChristian Weber, Serge Kocher, Kurt Neeser, et al.
Pharmacoeconomics|April 6, 2004
Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspectiveKurt Neeser, Georg Lübben, Uwe Siebert, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessmentChristian Weber, Kurt Neeser, Berthold Schneider, et al.
Current Medical Research and Opinion|March 31, 2009
Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overviewChristian Weber, Serge Kocher, Kurt Neeser, et al.
Journal of Comparative Effectiveness Research|April 3, 2019
Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapyKurt Neeser, William M O'Neil, Lee Stern, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2007
Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factorsKurt Neeser, Thomas Szucs, Jean-Luc Bulliard, et al.
Swiss Medical Weekly|November 9, 2007
Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11)Christian Weber, Berthold Schneider, Volker Lodwig, et al.
Pageof 2